FDA Approved Products

6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
CANTIL
mepenzolate bromide
LOE Approaching
Sanofi
ORAL · TABLET
1956
NDA
30/100
CAPASTAT SULFATE
capreomycin sulfate
LOE Approaching
INJECTION · INJECTABLE
1971
NDA
30/100
CAPEX
fluocinolone acetonide
LOE Approaching
Galderma
TOPICAL · SHAMPOO
1990
NDA
30/100
CAPITAL SOLEIL 15
avobenzone; ecamsule; octocrylene
LOE Approaching
TOPICAL · CREAM
Sunburnswind burned+1
2006
NDA
30/100
CAPITROL
chloroxine
LOE Approaching
TOPICAL · SHAMPOO
1976
NDA
30/100
CAPOTEN
captopril
LOE Approaching
ORAL · TABLET
hypertensiondiabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus+7
1981
SMNDA
30/100
CAPOZIDE 25/15
captopril; hydrochlorothiazide
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
hypertensiondiabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus+7
1984
NDA
30/100
CAPOZIDE 25/25
captopril; hydrochlorothiazide
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
hypertensiondiabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus+7
1984
NDA
30/100
CAPOZIDE 50/15
captopril; hydrochlorothiazide
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
hypertensiondiabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus+7
1984
NDA
30/100
CAPOZIDE 50/25
captopril; hydrochlorothiazide
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
hypertensiondiabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus+7
1984
NDA
30/100
CARAC
fluorouracil cream, 0.5%
LOE Approaching
TOPICAL · CREAM
2000
NDA
30/100
CARAFATE
sucralfate
LOE Approaching
AbbVie
ORAL · TABLET
1981
NDA
30/100
CARAFATE
sucralfate
LOE Approaching
AbbVie
ORAL · SUSPENSION
the short-term (up to 8 weeks) treatment of active duodenal ulcer
1993
NDA
30/100
CARBAGLU
carglumic acid
LOE Approaching
Recordati
ORAL · TABLET, FOR SUSPENSION
2010
NDA
30/100
CARBATROL
carbamazepine
LOE Approaching
Takeda
ORAL · CAPSULE, EXTENDED RELEASE
the treatment of the pain associated with true trigeminal neuralgiaEpilepsy
1997
NDA
30/100
CARBOCAINE
mepivacaine hydrochloride
LOE Approaching
INJECTION · INJECTABLE
1960
NDA
30/100
CARBOCAINE
mepivacaine hydrochloride
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1960
NDA
30/100
CARBOCAINE W/ NEO-COBEFRIN
levonordefrin; mepivacaine hydrochloride
LOE Approaching
INJECTION · INJECTABLE
1960
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Peak
INHALATION · GAS
2014
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Peak
Carbon Biosciences
INHALATION · GAS
2013
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Launch
INHALATION · GAS
2025
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Peak
INHALATION · GAS
2013
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Growth
INHALATION · GAS
2024
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Peak
INHALATION · GAS
2013
NDA
30/100
← PreviousPage 27 of 277Next →